Ethic Inc. Reduces Holdings in Koninklijke Philips N.V. $PHG

Ethic Inc. lowered its position in Koninklijke Philips N.V. (NYSE:PHG) by 4.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 34,847 shares of the technology company’s stock after selling 1,497 shares during the period. Ethic Inc.’s holdings in Koninklijke Philips were worth $841,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Cerity Partners LLC raised its position in Koninklijke Philips by 30.6% in the 1st quarter. Cerity Partners LLC now owns 80,767 shares of the technology company’s stock worth $2,051,000 after purchasing an additional 18,906 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Koninklijke Philips by 2.5% in the first quarter. Dimensional Fund Advisors LP now owns 4,396,095 shares of the technology company’s stock worth $111,662,000 after buying an additional 106,044 shares during the period. HB Wealth Management LLC bought a new stake in shares of Koninklijke Philips during the 1st quarter worth approximately $333,000. Bessemer Group Inc. boosted its holdings in Koninklijke Philips by 2,935.4% during the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company’s stock valued at $51,000 after acquiring an additional 1,908 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Koninklijke Philips by 18.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 72,276 shares of the technology company’s stock valued at $1,836,000 after acquiring an additional 11,018 shares during the period. Institutional investors own 13.67% of the company’s stock.

Analyst Upgrades and Downgrades

PHG has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Koninklijke Philips in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Koninklijke Philips Stock Up 0.2%

Shares of NYSE PHG opened at $28.90 on Tuesday. Koninklijke Philips N.V. has a 12-month low of $21.48 and a 12-month high of $29.29. The stock’s fifty day simple moving average is $27.88 and its two-hundred day simple moving average is $25.62. The stock has a market capitalization of $27.82 billion, a PE ratio of 152.08, a price-to-earnings-growth ratio of 0.78 and a beta of 0.82. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.69.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings data on Tuesday, July 29th. The technology company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%.The company had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $4.35 billion. As a group, analysts expect that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.